Evidence supporting the use of: Amyloban
For the health condition: Schizophrenia
Synopsis
Source of validity: Scientific
Rating (out of 5): 1
Amyloban is a proprietary extract derived from the mushroom Hericium erinaceus (Lion’s Mane), standardized for compounds called amyloban and hericenones, which are thought to have neurotrophic effects. Some preliminary scientific investigations, mostly from Japan, have explored its use as an adjunctive treatment for schizophrenia. The primary evidence comes from small open-label studies and case reports, such as a 2010 pilot study by Mori et al., which suggested that Amyloban3399 might be beneficial for patients with treatment-resistant schizophrenia, particularly in reducing symptoms like hallucinations when added to standard antipsychotic therapy. However, these studies are limited by small sample sizes, lack of placebo controls, and short durations.
There is little to no tradition of using Lion’s Mane or Amyloban specifically for schizophrenia in historical herbal or folk medicine. The rationale for its use is based on its putative neuroprotective and neurotrophic properties, as well as possible modulation of neuroinflammation. Overall, the scientific evidence remains very preliminary and insufficient to draw firm conclusions about efficacy or safety for schizophrenia. No major clinical guidelines recommend Amyloban, and large-scale, placebo-controlled trials are lacking. Thus, while there is some scientific interest and very low-level evidence, the support for its use in schizophrenia is weak.
Other health conditions supported by Amyloban
Alzheimer's DiseaseDementia
Memory and Brain Function
Schizophrenia